The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The requested target is unambiguous: UniProt Q07889 is human Son of sevenless homolog 1 (SOS1), a 1,333-amino-acid, approximately 150-kDa multidomain guanine-nucleotide exchange factor (GEF). Its established primary function is to activate membrane-associated RAS proteins by accelerating release of bound GDP and Mg²⁺; GTP subsequently binds from the cellular nucleotide pool. Thus, SOS1 is not a kinase and does not chemically transfer GTP—it catalyzes the nucleotide-release step that changes RAS from its inactive GDP-bound state to its signaling-competent GTP-bound state. The protein acts mainly at the cytoplasmic face of the plasma membrane, where receptor/adaptor, lipid, and RAS interactions recruit and activate it. (bandaru2019theinterdependentactivation pages 3-4, kessler2021targetingsonof pages 1-2, sondermann2003tandemhistonefolds pages 1-2)
Its best-established pathway position is activated receptor tyrosine kinase (RTK) → GRB2 → SOS1 → RAS-GTP → RAF → MEK → ERK. Germline gain-of-function variants cause Noonan syndrome and related RASopathy phenotypes; a distinct truncating gain-of-function mechanism causes hereditary gingival fibromatosis type 1. In cancer, activating SOS1 mutations are uncommon, but many RTK- or KRAS-dependent tumors remain dependent on SOS1-mediated nucleotide loading. Small-molecule SOS1 inhibition is therefore an active but still investigational therapeutic strategy. (pierre2011understandingsos(son pages 5-8, pierre2011understandingsos(son pages 17-23, kessler2021targetingsonof pages 1-2)
| Feature | Best-supported annotation | Evidence type/strength |
|---|---|---|
| Exact identity | Human SOS1, UniProt Q07889; 1,333-aa Son of sevenless homolog 1, a multidomain Cdc25-family guanine-nucleotide exchange factor (GEF). (kessler2021targetingsonof pages 1-2) | High: accession-specific peer-reviewed review and concordant structural literature. |
| Domain architecture | N→C order: tandem histone folds–DH–PH–REM–CDC25–proline-rich tail. This agrees with the supplied histone-fold, DH/DBL and PH-domain annotations; REM–CDC25 forms the Ras-exchange module. (bandaru2019theinterdependentactivation pages 3-4, kessler2021targetingsonof pages 1-2, sondermann2003tandemhistonefolds pages 1-2) | High: crystallography, sequence architecture and multiple reviews. |
| Primary substrate specificity | Exchanges nucleotides on H-RAS, N-RAS and K-RAS; KRAS is emphasized therapeutically because of its major oncogenic role. A reported biochemical preference is H-RAS > N-RAS > K-RAS, but all three are substrates. (bandaru2019theinterdependentactivation pages 3-4, rojas2011mammaliansonof pages 4-5, kessler2021targetingsonof pages 1-2) | High for pan-RAS activity; moderate for the isoform-preference ranking. |
| Catalyzed reaction | SOS1 does not transfer or synthesize GTP. Its CDC25 helical hairpin disrupts Ras switch-region/nucleotide–Mg²⁺ interactions, accelerates GDP/Mg²⁺ release, and stabilizes nucleotide-free Ras; abundant cellular GTP then binds passively. (bandaru2019theinterdependentactivation pages 3-4, sondermann2003tandemhistonefolds pages 1-2, kamel2026disruptingthekras–sos1 pages 6-7) | High: structural and biochemical mechanism. |
| Catalytic versus allosteric sites | The CDC25 catalytic site binds substrate Ras and promotes nucleotide release. A distinct site at the REM–CDC25 interface preferentially binds Ras–GTP, stabilizing an exchange-competent conformation and creating positive feedback. (bandaru2019theinterdependentactivation pages 3-4, kessler2021targetingsonof pages 1-2, bandaru2019theinterdependentactivation pages 6-8) | High: structures plus nucleotide-exchange assays. |
| Autoinhibition | N-terminal histone/DH–PH elements fold against the catalytic module and obstruct the allosteric Ras site; the helical linker and C-terminal tail also restrain activity. Membrane lipids and Ras–GTP help relieve this inhibition. (yadav2010allostericgatingof pages 1-3, bandaru2019theinterdependentactivation pages 3-4, sondermann2003tandemhistonefolds pages 1-2) | High: structures, truncation experiments and mutational/cell assays. |
| Site of action and recruitment | SOS1 is primarily cytosolic when inactive but performs Ras exchange at the cytosolic face of the plasma membrane. Activated RTKs recruit GRB2 through phosphotyrosine–SH2 contacts, while GRB2 SH3 domains bind SOS1’s proline-rich tail; PH/histone-region interactions with PIP₂ or phosphatidic acid and allosteric Ras–GTP further stabilize membrane engagement. (yadav2010allostericgatingof pages 1-3, bandaru2019theinterdependentactivation pages 3-4, pierre2011understandingsos(son pages 5-8) | High: receptor-signaling, lipid-binding, mutational and localization evidence. |
| Canonical pathway output | RTK→GRB2→SOS1→RAS-GTP→RAF→MEK→ERK. SOS1 directly catalyzes only the Ras exchange step; RAF–MEK–ERK activation is downstream. ERK phosphorylation of the SOS1 tail can disrupt GRB2–SOS1 binding, providing negative feedback. (pierre2011understandingsos(son pages 5-8, kessler2021targetingsonof pages 1-2) | High: canonical biochemical and cellular-signaling evidence. |
| RAC-related role | SOS1 participates in RAC/cytoskeletal signaling, including an EPS8–E3B1/ABI1 complex, but whether its DH domain is an autonomous physiological RAC-GEF is contested and less certain: some reports assign DH–PH exchange activity, whereas structural/biochemical work found the isolated module inactive. (sondermann2003tandemhistonefolds pages 1-2, pierre2011understandingsos(son pages 5-8, rojas2011mammaliansonof pages 3-4, bandaru2019theinterdependentactivation pages 6-8) | Moderate/contested: context-dependent and conflicting evidence; weaker than the Ras-GEF assignment. |
| Inherited disease | Germline gain-of-function or autoinhibition-disrupting variants cause Noonan syndrome/RASopathy; truncating gain-of-function variants cause hereditary gingival fibromatosis type 1. SOS1 variants account for an estimated 13%–20% of Noonan syndrome in an earlier synthesis. (OpenTargets Search: -SOS1, pierre2011understandingsos(son pages 17-23, rojas2011mammaliansonof pages 4-5) | High: human genetics, segregation, structural interpretation and functional signaling studies. |
| Cancer relevance | Somatic activating SOS1 mutations are uncommon, but cancers can depend on SOS1-mediated nucleotide loading downstream of RTKs or mutant KRAS. A 2024 patient-derived NSCLC model with SOS1 P481delinsLFFL was sensitive to BAY-293, MRTX0902 and BI-3406. (pierre2011understandingsos(son pages 17-23, kessler2021targetingsonof pages 1-2, hamilton2024characterizationofthe pages 1-2) | High for pathway dependency; emerging for rare SOS1-mutant tumors. |
| Translational status | SOS1 inhibition remains investigational, with no established clinical application supported here. BAY-293 and BI-3406 are principally preclinical tools; BI-1701963 and MRTX0902 entered early-phase trials. Current registry records show MRTX0902 NCT05578092 terminated after 64 participants and several small BI-1701963 studies terminated, while NCT04111458 remains active but not recruiting with 71 participants and no posted efficacy results in the cited record. (li2024leadidentificationof pages 1-3, NCT05578092 chunk 1, NCT04975256 chunk 1, NCT04111458 chunk 1, NCT04835714 chunk 1) | Early clinical/inconclusive: strong target-engagement rationale and preclinical activity, but limited public clinical evidence. |
Table: Compact evidence-weighted annotation of human SOS1/Q07889, covering its architecture, Ras-exchange mechanism, membrane-localized signaling role, disease associations, and investigational therapeutic status.
The literature explicitly maps UniProtKB Q07889 to human SOS1, “Son of sevenless homolog 1.” It describes the protein as a 1,333-residue Cdc25-homology-family GEF. This agrees with the supplied gene symbol, protein description and organism, Homo sapiens. Human SOS2 is a separate paralogue, not the target considered here. (bandaru2019theinterdependentactivation pages 3-4, kessler2021targetingsonof pages 1-2)
No literature concerning a different organism’s SOS/Cdc25 protein was used to assign function to Q07889. This distinction matters because fungal and other nonhuman Ras GEFs can have substantially different regulatory properties.
The experimentally established N-to-C architecture is:
tandem histone folds → Dbl-homology (DH) domain → pleckstrin-homology (PH) domain → Ras exchanger motif (REM) → Cdc25 catalytic domain → proline-rich C-terminal tail. (bandaru2019theinterdependentactivation pages 3-4, kessler2021targetingsonof pages 1-2, sondermann2003tandemhistonefolds pages 1-2)
This architecture agrees with the supplied InterPro calls—histone fold, DH/DBL and PH/PH-like domains—but the supplied list is incomplete as a functional description because the central REM–Cdc25 module is indispensable for Ras exchange. The “DBL” annotation does not mean that SOS1’s principal physiological substrate is necessarily a Rho-family GTPase; its unequivocal primary catalytic assignment is as a RAS GEF.
SOS1 catalyzes the effective reaction:
RAS·GDP·Mg²⁺ → RAS·nucleotide-free intermediate → RAS·GTP·Mg²⁺.
The Cdc25-domain helical hairpin engages the RAS switch regions and disrupts the nucleotide/Mg²⁺-binding environment, sharply accelerating GDP release. SOS1 stabilizes nucleotide-free RAS transiently; after complex dissociation, GTP binds because it is abundant in the cytosol. Consequently, SOS1 catalyzes GDP dissociation, not GTP synthesis or covalent transfer. (bandaru2019theinterdependentactivation pages 3-4, sondermann2003tandemhistonefolds pages 1-2, kamel2026disruptingthekras–sos1 pages 6-7)
SOS1 can activate the three principal vertebrate RAS isoforms—H-RAS, N-RAS and K-RAS. An older biochemical synthesis reported the preference H-RAS > N-RAS > K-RAS, although all three are established substrates and KRAS dominates current therapeutic research because of its oncogenic prevalence. (bandaru2019theinterdependentactivation pages 3-4, rojas2011mammaliansonof pages 4-5)
SOS1 is therefore better described as a broad canonical RAS GEF rather than a KRAS-exclusive enzyme. Its inhibitor literature often uses “SOS1–KRAS” because KRAS-mutant tumors are the primary translational setting.
SOS1 contains two functionally distinct RAS-binding sites:
This creates positive feedback: an initial pool of RAS-GTP activates SOS1 allosterically, allowing SOS1 to generate additional RAS-GTP. This architecture helps explain switch-like or pulsatile RAS activation rather than a simple linear input-output relationship.
Full-length cytosolic SOS1 is strongly autoinhibited. The N-terminal histone/DH–PH region folds against the catalytic module and sterically restricts access to the allosteric RAS site; the DH–REM contact and helical linker help maintain this closed state. The C-terminal tail also restrains activity, as truncation of either the first approximately 550 residues or the tail increases REM–Cdc25 activity. (yadav2010allostericgatingof pages 1-3, bandaru2019theinterdependentactivation pages 3-4, sondermann2003tandemhistonefolds pages 1-2)
This model is supported by crystallography, truncation experiments, lipid-binding studies and disease mutations. For example, the Noonan-associated E108K histone-region mutation increased apparent phosphatidic-acid affinity approximately fourfold, caused constitutive membrane association, and enhanced basal and prolonged EGF-induced RAS activation. (yadav2010allostericgatingof pages 1-3)
Several cooperative inputs overcome autoinhibition:
The resulting expert model is that SOS1 activity is governed by coincidence detection: receptor recruitment alone is insufficient for maximal activation; receptor proximity, the membrane lipid environment, relief of conformational autoinhibition and allosteric RAS occupancy cooperate.
Inactive SOS1 is predominantly a soluble cytoplasmic protein. Its principal catalytic work occurs transiently at the inner, cytoplasmic leaflet of the plasma membrane, because lipid-modified RAS substrates reside there. After RTK phosphorylation, the GRB2 SH2 domain recognizes receptor phosphotyrosines directly or through SHC, while GRB2 SH3 domains bind PXXP motifs in SOS1’s proline-rich tail. This brings SOS1 into contact with membrane RAS. (bandaru2019theinterdependentactivation pages 3-4, pierre2011understandingsos(son pages 5-8)
PH-domain binding to acidic lipids and allosteric binding to membrane-associated RAS further increase membrane residence and productive orientation. SOS1 should therefore not be annotated as an integral membrane protein or extracellular factor; it is a peripheral, stimulus-recruited cytoplasmic signaling enzyme.
The core pathway is:
growth factor → RTK phosphorylation → GRB2/SOS1 recruitment → RAS-GTP → RAF → MEK → ERK.
SOS1 directly performs only the RAS nucleotide-exchange step. RAF, MEK and ERK activation are downstream consequences of increased RAS-GTP. Depending on cellular context and signal dynamics, this axis controls proliferation, differentiation, survival and migration. (pierre2011understandingsos(son pages 5-8, kessler2021targetingsonof pages 1-2)
SOS1 also participates in feedback control. ERK-mediated phosphorylation near C-terminal SH3-binding sites weakens the GRB2–SOS1 interaction, helping terminate receptor-driven RAS activation. Other feedback proteins and changes in GRB2 complexes provide additional attenuation. (kessler2021targetingsonof pages 1-2, pierre2011understandingsos(son pages 5-8)
Some literature describes SOS1 as a dual RAS/RAC GEF. In this model, its DH–PH region and an EPS8–E3B1/ABI1–SOS1 complex promote RAC activation, JNK signaling, actin remodeling and migration. (pierre2011understandingsos(son pages 1-5, pierre2011understandingsos(son pages 5-8, rojas2011mammaliansonof pages 3-4)
However, this assignment is less secure than the RAS-GEF function. The isolated SOS1 DH–PH unit showed no detectable exchange activity in solution and appeared inactive crystallographically; a modern mechanistic review explicitly concluded that the DH domain is not active as an autonomous Rho-family GEF. SOS1 may therefore promote RAC signaling in a context-dependent complex or adaptor capacity rather than as a constitutively competent DH-domain exchange enzyme. (sondermann2003tandemhistonefolds pages 1-2, bandaru2019theinterdependentactivation pages 6-8)
Recommended functional annotation: “RAS guanine-nucleotide exchange factor; participates in context-dependent RAC/cytoskeletal signaling,” rather than treating RAS and RAC catalytic activities as equally established.
Germline SOS1 gain-of-function variants cause a distinctive form of Noonan syndrome, generally by destabilizing autoinhibitory contacts, reorienting regulatory domains or increasing plasma-membrane recruitment. An earlier synthesis estimated SOS1 variants in approximately 13%–20% of Noonan syndrome cases. The mechanistic commonality is excess RAS–MAPK signaling during development. (pierre2011understandingsos(son pages 17-23, rojas2011mammaliansonof pages 4-5)
Open Targets independently reports strong SOS1 associations with Noonan syndrome, Noonan-related syndromes and RASopathy, with association scores around 0.87 in the retrieved record. These database scores summarize heterogeneous evidence and should not replace the underlying human-genetic studies. (OpenTargets Search: -SOS1)
SOS1 variants also cause hereditary gingival fibromatosis type 1. The classic mechanism involves an exon-21 insertion producing a truncated gain-of-function protein that loses part of the regulatory proline-rich tail, increases ERK signaling and promotes gingival-fibroblast proliferation. This is mechanistically distinct from many Noonan variants but converges on excessive SOS1/RAS pathway output. (rojas2011mammaliansonof pages 2-3, rojas2011mammaliansonof pages 4-5)
Somatic activating SOS1 mutations are uncommon compared with oncogenic KRAS, EGFR or loss of NF1. Nevertheless, SOS1 can be a crucial pathway dependency in tumors driven by upstream RTKs or by RAS alleles that continue cycling through GDP- and GTP-bound states. This distinction is important: SOS1 is more often a required signaling node than a frequently mutated oncogene. (pierre2011understandingsos(son pages 17-23, kessler2021targetingsonof pages 1-2)
A notable 2024 example is BH1406, a patient-derived NSCLC line carrying the rare activating SOS1 P481delinsLFFL alteration. Whole-exome sequencing found the variant after a limited diagnostic panel failed to identify a driver. The cells were sensitive to BAY-293, MRTX0902 and BI-3406; 3D cultures showed ERK1/2 activation that remained SOS1-inhibitor-sensitive. This is compelling functional evidence for druggability of a rare SOS1-driven tumor, but it remains a single-model preclinical study rather than clinical proof. The paper was published online 28 November 2024: https://doi.org/10.21037/tlcr-24-570. (hamilton2024characterizationofthe pages 1-2, hamilton2024characterizationofthe pages 2-4)
The major drug-discovery strategy is to occupy a pocket adjacent to the catalytic RAS interface, thereby preventing productive SOS1–RAS complex formation and reducing RAS-GTP. BAY-293 established chemical tractability, with a biochemical SOS1–KRAS interaction IC₅₀ of 21 nM, although cellular antiproliferative concentrations were much higher and selectivity between oncogenic and wild-type KRAS contexts was limited. (li2024leadidentificationof pages 1-3, lunaramirez2026sos1trackingthe pages 5-7)
BI-3406 is a selective preclinical SOS1 inhibitor. Reported values include 5 nM inhibition of SOS1 interaction with GDP-bound KRAS, RAS-GTP inhibition at 83–231 nM, and pERK reduction at 17–57 nM in selected models. These results support target engagement but also show that biochemical affinity does not translate directly into uniform cellular potency. (kamel2026disruptingthekras–sos1 pages 13-14, lunaramirez2026sos1trackingthe pages 5-7)
MRTX0902 was reported in 2024 to inhibit KRAS activation and tumors dependent on KRAS nucleotide loading. Preclinical evidence indicates activity across multiple relevant genetic contexts and supports combinations with allele-specific KRAS inhibitors. Its rationale is strongest for RAS proteins that retain appreciable GDP/GTP cycling; strongly exchange-independent alleles or bypass signaling may be less responsive. The original 2024 study is available at https://doi.org/10.1158/1535-7163.MCT-23-0870. (lunaramirez2026sos1trackingthe pages 25-26, zeng2026computationalinsightson pages 17-19)
Li and colleagues reported HH0043, a 1,7-naphthyridine SOS1 inhibitor, on 3 June 2024. In a KRAS-G12C NCI-H358 xenograft model, oral HH0043 achieved 76% tumor-growth inhibition, compared with 49% for BI-3406 at the same dose. These are animal efficacy data, not response rates in patients. DOI: https://doi.org/10.1021/acsmedchemlett.4c00156. (li2024leadidentificationof pages 1-3)
A 2024 random-forest virtual-screening study searched the Chinese National Compound Library of more than 1.4 million compounds and identified nine previously unexplored chemical frameworks with inhibitory activity. The leading hits produced more than 50% inhibition in a KRAS-G12C/SOS1 interaction assay; the reported IC₅₀ was approximately 20 μg/mL, indicating an early hit rather than a development-ready drug. The work was accepted 14 March 2024: https://doi.org/10.1039/d4md00063c. (duo2024discoveryofnovel pages 1-2)
The prevailing expert rationale favors combinations because SOS1 blockade can be cytostatic and signaling networks rapidly adapt. Preclinical combinations include SOS1 inhibitors with:
These combinations are biologically rational, but efficacy and tolerability must be established clinically; additive suppression of normal RTK–RAS signaling is a potential therapeutic-window constraint.
Current real-world uses are primarily investigational:
No approved SOS1-directed therapy is supported by the retrieved evidence. Current registry records show a mixed and still inconclusive early-phase landscape:
Trial termination for business or strategic reasons cannot be equated with proof that the mechanism is ineffective. Conversely, preclinical potency should not be interpreted as clinical validation. The authoritative conclusion is that SOS1 inhibition remains experimentally and clinically investigational.
The highest-confidence annotation is narrow and mechanistic: SOS1 is a stimulus-regulated, membrane-recruited GEF that catalyzes nucleotide release from RAS. Its biological importance follows from where and when that reaction occurs. GRB2-mediated receptor recruitment places SOS1 next to lipid-anchored RAS; membrane lipids and RAS-GTP relieve autoinhibition; allosteric positive feedback then amplifies the signal. This mechanistic chain is more informative than broadly labeling SOS1 as a generic regulator of proliferation.
Three qualifications are essential:
SOS1/Q07889 is a human, multidomain RAS guanine-nucleotide exchange factor. At the cytoplasmic plasma-membrane surface, it is recruited downstream of activated receptors—principally through GRB2—and catalyzes GDP/Mg²⁺ release from H-, N- and K-RAS. The Cdc25 domain is catalytic, whereas the REM–Cdc25 interface binds RAS-GTP allosterically to create positive feedback. Histone-fold, DH–PH, linker and C-terminal elements regulate localization and autoinhibition. Its dominant pathway output is RAS–RAF–MEK–ERK signaling; context-dependent RAC/cytoskeletal signaling is plausible but mechanistically less secure. Germline gain-of-function causes Noonan syndrome/RASopathy and hereditary gingival fibromatosis, while cancer relevance more commonly reflects pathway dependence than recurrent SOS1 mutation. SOS1-directed drugs remain investigational.
References
(bandaru2019theinterdependentactivation pages 3-4): Pradeep Bandaru, Yasushi Kondo, and John Kuriyan. The interdependent activation of son-of-sevenless and ras. Cold Spring Harbor perspectives in medicine, 9 2:a031534, Feb 2019. URL: https://doi.org/10.1101/cshperspect.a031534, doi:10.1101/cshperspect.a031534. This article has 95 citations and is from a peer-reviewed journal.
(kessler2021targetingsonof pages 1-2): Dirk Kessler, Daniel Gerlach, Norbert Kraut, and Darryl B. McConnell. Targeting son of sevenless 1: the pacemaker of kras. Current Opinion in Chemical Biology, 62:109-118, Jun 2021. URL: https://doi.org/10.1016/j.cbpa.2021.02.014, doi:10.1016/j.cbpa.2021.02.014. This article has 103 citations and is from a peer-reviewed journal.
(sondermann2003tandemhistonefolds pages 1-2): Holger Sondermann, Stephen M Soisson, Dafna Bar-Sagi, and John Kuriyan. Tandem histone folds in the structure of the n-terminal segment of the ras activator son of sevenless. Structure, 11 12:1583-93, Dec 2003. URL: https://doi.org/10.1016/j.str.2003.10.015, doi:10.1016/j.str.2003.10.015. This article has 63 citations and is from a domain leading peer-reviewed journal.
(pierre2011understandingsos(son pages 5-8): Stéphane Pierre, Anne-Sophie bats, and Xavier Coumoul. Understanding sos (son of sevenless). Biochemical pharmacology, 82 9:1049-56, Nov 2011. URL: https://doi.org/10.1016/j.bcp.2011.07.072, doi:10.1016/j.bcp.2011.07.072. This article has 107 citations and is from a domain leading peer-reviewed journal.
(pierre2011understandingsos(son pages 17-23): Stéphane Pierre, Anne-Sophie bats, and Xavier Coumoul. Understanding sos (son of sevenless). Biochemical pharmacology, 82 9:1049-56, Nov 2011. URL: https://doi.org/10.1016/j.bcp.2011.07.072, doi:10.1016/j.bcp.2011.07.072. This article has 107 citations and is from a domain leading peer-reviewed journal.
(rojas2011mammaliansonof pages 4-5): J. M. Rojas, J. L. Oliva, and E. Santos. Mammalian son of sevenless guanine nucleotide exchange factors: old concepts and new perspectives. Genes & cancer, 2 3:298-305, Mar 2011. URL: https://doi.org/10.1177/1947601911408078, doi:10.1177/1947601911408078. This article has 117 citations.
(kamel2026disruptingthekras–sos1 pages 6-7): Emadeldin M. Kamel, Sally Mostafa Khadrawy, Mohamed A. M. Ali, Mostafa R. Abukhadra, Nour Y. S. Yassin, Saleh Alkhedhairi, Faris F. Aba Alkhayl, and Al Mokhtar Lamsabhi. Disrupting the kras–sos1 protein–protein interaction: mechanistic rationale for pan-kras pathway suppression and combination therapy. Frontiers in Chemistry, Apr 2026. URL: https://doi.org/10.3389/fchem.2026.1808601, doi:10.3389/fchem.2026.1808601. This article has 1 citations.
(bandaru2019theinterdependentactivation pages 6-8): Pradeep Bandaru, Yasushi Kondo, and John Kuriyan. The interdependent activation of son-of-sevenless and ras. Cold Spring Harbor perspectives in medicine, 9 2:a031534, Feb 2019. URL: https://doi.org/10.1101/cshperspect.a031534, doi:10.1101/cshperspect.a031534. This article has 95 citations and is from a peer-reviewed journal.
(yadav2010allostericgatingof pages 1-3): Kamlesh K. Yadav and Dafna Bar-Sagi. Allosteric gating of son of sevenless activity by the histone domain. Proceedings of the National Academy of Sciences, 107:3436-3440, Feb 2010. URL: https://doi.org/10.1073/pnas.0914315107, doi:10.1073/pnas.0914315107. This article has 68 citations and is from a highest quality peer-reviewed journal.
(rojas2011mammaliansonof pages 3-4): J. M. Rojas, J. L. Oliva, and E. Santos. Mammalian son of sevenless guanine nucleotide exchange factors: old concepts and new perspectives. Genes & cancer, 2 3:298-305, Mar 2011. URL: https://doi.org/10.1177/1947601911408078, doi:10.1177/1947601911408078. This article has 117 citations.
(OpenTargets Search: -SOS1): Open Targets Query (-SOS1, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(hamilton2024characterizationofthe pages 1-2): Gerhard Hamilton, Sandra Stickler, Mikhail Ermakov, Marie-Therese Eggerstorfer, Francesca Paola Nocera, Martin Hohenegger, Lukas Weigl, Maximilian Johannes Hochmair, and Karl Kashofer. Characterization of the bh1406 non-small cell lung cancer (nsclc) cell line carrying an activating sos1 mutation. Translational Lung Cancer Research, 13:2987-2997, Nov 2024. URL: https://doi.org/10.21037/tlcr-24-570, doi:10.21037/tlcr-24-570. This article has 2 citations and is from a peer-reviewed journal.
(li2024leadidentificationof pages 1-3): Dongsheng Li, Qing Xie, Maozhi Yang, Yalei Cai, Kang‐Ping Sun, Shujuan Jiang, Songda Yu, Lei Liu, Yixiang Zhang, Bing Yu, Wangyang Tu, and Leping Li. Lead identification of novel naphthyridine derivatives as potent sos1 inhibitors. ACS medicinal chemistry letters, 15 6:958-964, Jun 2024. URL: https://doi.org/10.1021/acsmedchemlett.4c00156, doi:10.1021/acsmedchemlett.4c00156. This article has 9 citations and is from a peer-reviewed journal.
(NCT05578092 chunk 1): A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway. Mirati Therapeutics Inc.. 2022. ClinicalTrials.gov Identifier: NCT05578092
(NCT04975256 chunk 1): Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14). Mirati Therapeutics Inc.. 2021. ClinicalTrials.gov Identifier: NCT04975256
(NCT04111458 chunk 1): A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation). Boehringer Ingelheim. 2019. ClinicalTrials.gov Identifier: NCT04111458
(NCT04835714 chunk 1): A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS]). Boehringer Ingelheim. 2021. ClinicalTrials.gov Identifier: NCT04835714
(pierre2011understandingsos(son pages 1-5): Stéphane Pierre, Anne-Sophie bats, and Xavier Coumoul. Understanding sos (son of sevenless). Biochemical pharmacology, 82 9:1049-56, Nov 2011. URL: https://doi.org/10.1016/j.bcp.2011.07.072, doi:10.1016/j.bcp.2011.07.072. This article has 107 citations and is from a domain leading peer-reviewed journal.
(rojas2011mammaliansonof pages 2-3): J. M. Rojas, J. L. Oliva, and E. Santos. Mammalian son of sevenless guanine nucleotide exchange factors: old concepts and new perspectives. Genes & cancer, 2 3:298-305, Mar 2011. URL: https://doi.org/10.1177/1947601911408078, doi:10.1177/1947601911408078. This article has 117 citations.
(hamilton2024characterizationofthe pages 2-4): Gerhard Hamilton, Sandra Stickler, Mikhail Ermakov, Marie-Therese Eggerstorfer, Francesca Paola Nocera, Martin Hohenegger, Lukas Weigl, Maximilian Johannes Hochmair, and Karl Kashofer. Characterization of the bh1406 non-small cell lung cancer (nsclc) cell line carrying an activating sos1 mutation. Translational Lung Cancer Research, 13:2987-2997, Nov 2024. URL: https://doi.org/10.21037/tlcr-24-570, doi:10.21037/tlcr-24-570. This article has 2 citations and is from a peer-reviewed journal.
(lunaramirez2026sos1trackingthe pages 5-7): Luis Luna-Ramírez, Rósula García-Navas, Eugenio Santos, and Fernando C. Baltanás. Sos1: tracking the evolving path from promising to actionable therapeutic target in ras-dependent cancers. Molecular Cancer, Mar 2026. URL: https://doi.org/10.1186/s12943-026-02632-7, doi:10.1186/s12943-026-02632-7. This article has 1 citations and is from a highest quality peer-reviewed journal.
(kamel2026disruptingthekras–sos1 pages 13-14): Emadeldin M. Kamel, Sally Mostafa Khadrawy, Mohamed A. M. Ali, Mostafa R. Abukhadra, Nour Y. S. Yassin, Saleh Alkhedhairi, Faris F. Aba Alkhayl, and Al Mokhtar Lamsabhi. Disrupting the kras–sos1 protein–protein interaction: mechanistic rationale for pan-kras pathway suppression and combination therapy. Frontiers in Chemistry, Apr 2026. URL: https://doi.org/10.3389/fchem.2026.1808601, doi:10.3389/fchem.2026.1808601. This article has 1 citations.
(lunaramirez2026sos1trackingthe pages 25-26): Luis Luna-Ramírez, Rósula García-Navas, Eugenio Santos, and Fernando C. Baltanás. Sos1: tracking the evolving path from promising to actionable therapeutic target in ras-dependent cancers. Molecular Cancer, Mar 2026. URL: https://doi.org/10.1186/s12943-026-02632-7, doi:10.1186/s12943-026-02632-7. This article has 1 citations and is from a highest quality peer-reviewed journal.
(zeng2026computationalinsightson pages 17-19): Juanxian Zeng, Yixuan Lan, and Fei Xia. Computational insights on the molecular interplay between kras (g12d mutation) and sos1 modulated by the inhibitor bi-3406. PLOS Computational Biology, 22(4):e1014213, Apr 2026. URL: https://doi.org/10.1371/journal.pcbi.1014213, doi:10.1371/journal.pcbi.1014213. This article has 0 citations and is from a highest quality peer-reviewed journal.
(duo2024discoveryofnovel pages 1-2): Lihui Duo, Yi Chen, Qiupei Liu, Zhangyi Ma, Amin Farjudian, Wan Yong Ho, Sze Shin Low, Jianfeng Ren, Jonathan D. Hirst, Hua Xie, and Bencan Tang. Discovery of novel sos1 inhibitors using machine learning. RSC Medicinal Chemistry, 15:1392-1403, Mar 2024. URL: https://doi.org/10.1039/d4md00063c, doi:10.1039/d4md00063c. This article has 12 citations and is from a peer-reviewed journal.